Integrated Genomic Characterization of Papillary Thyroid Carcinoma

被引:2210
作者
Agrawal, Nishant
Akbani, Rehan
Aksoy, B. Arman
Ally, Adrian
Arachchi, Harindra
Asa, Sylvia L.
Auman, J. Todd
Balasundaram, Miruna
Balu, Saianand
Baylin, Stephen B.
Behera, Madhusmita
Bernard, Brady
Beroukhim, Rameen
Bishop, Justin A.
Black, Aaron D.
Bodenheimer, Tom
Boice, Lori
Bootwalla, Moiz S.
Bowen, Jay
Bowlby, Reanne
Bristow, Christopher A.
Brookens, Robin
Brooks, Denise
Bryant, Robert
Buda, Elizabeth
Butterfield, Yaron S. N.
Carling, Tobias
Carlsen, Rebecca
Carter, Scott L.
Carty, Sally E.
Chan, Timothy A.
Chen, Amy Y.
Cherniack, Andrew D.
Cheung, Dorothy
Chin, Lynda
Cho, Juok
Chu, Andy
Chuah, Eric
Cibulskis, Kristian
Ciriello, Giovanni
Clarke, Amanda
Clayman, Gary L.
Cope, Leslie
Copland, John A.
Covington, Kyle
Danilova, Ludmila
Davidsen, Tanja
Demchok, John A.
DiCara, Daniel
Dhalla, Noreen
机构
[1] NCI, Canc Genome Atlas Program Off, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
ACTIVATED RAS ONCOGENES; TERT PROMOTER MUTATIONS; BRAF MUTATIONS; HUMAN CANCERS; PATHWAY; FUSION; GENES; CELLS; BRAF(V600E); NODULES;
D O I
10.1016/j.cell.2014.09.050
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we describe the genomic landscape of 496 PTCs. We observed a low frequency of somatic alterations (relative to other carcinomas) and extended the set of known PTC driver alterations to include EIF1AX, PPM1D, and CHEK2 and diverse gene fusions. These discoveries reduced the fraction of PTC cases with unknown oncogenic driver from 25% to 3.5%. Combined analyses of genomic variants, gene expression, and methylation demonstrated that different driver groups lead to different pathologies with distinct signaling and differentiation characteristics. Similarly, we identified distinct molecular subgroups of BRAF-mutant tumors, and multidimensional analyses highlighted a potential involvement of onco-miRs in less-differentiated subgroups. Our results propose a reclassification of thyroid cancers into molecular subtypes that better reflect their underlying signaling and differentiation properties, which has the potential to improve their pathological classification and better inform the management of the disease.
引用
收藏
页码:676 / 690
页数:15
相关论文
共 69 条
  • [1] Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas
    Adeniran, AJ
    Zhu, ZW
    Gandhi, M
    Steward, DL
    Fidler, JP
    Giordano, TJ
    Biddinger, PW
    Nikiforov, YE
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (02) : 216 - 222
  • [2] Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology
    Alexander, Erik K.
    Kennedy, Giulia C.
    Baloch, Zubair W.
    Cibas, Edmund S.
    Chudova, Darya
    Diggans, James
    Friedman, Lyssa
    Kloos, Richard T.
    LiVolsi, Virginia A.
    Mandel, Susan J.
    Raab, Stephen S.
    Rosai, Juan
    Steward, David L.
    Walsh, P. Sean
    Wilde, Jonathan I.
    Zeiger, Martha A.
    Lanman, Richard B.
    Haugen, Bryan R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (08) : 705 - 715
  • [3] IS ABOVE AGE 45 APPROPRIATE FOR UPSTAGING WELL-DIFFERENTIATED PAPILLARY THYROID CANCER?
    Bischoff, Lindsay A.
    Curry, Joseph
    Ahmed, Intekhab
    Pribitkin, Edmund
    Miller, Jeffrey L.
    [J]. ENDOCRINE PRACTICE, 2013, 19 (06) : 995 - 997
  • [4] Absolute quantification of somatic DNA alterations in human cancer
    Carter, Scott L.
    Cibulskis, Kristian
    Helman, Elena
    McKenna, Aaron
    Shen, Hui
    Zack, Travis
    Laird, Peter W.
    Onofrio, Robert C.
    Winckler, Wendy
    Weir, Barbara A.
    Beroukhim, Rameen
    Pellman, David
    Levine, Douglas A.
    Lander, Eric S.
    Meyerson, Matthew
    Getz, Gad
    [J]. NATURE BIOTECHNOLOGY, 2012, 30 (05) : 413 - +
  • [5] Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation
    Chakravarty, Debyani
    Santos, Elmer
    Ryder, Mabel
    Knauf, Jeffrey A.
    Liao, Xiao-Hui
    West, Brian L.
    Bollag, Gideon
    Kolesnick, Richard
    Thin, Tin Htwe
    Rosen, Neal
    Zanzonico, Pat
    Larson, Steven M.
    Refetoff, Samuel
    Ghossein, Ronald
    Fagin, James A.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (12) : 4700 - 4711
  • [6] Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse
    Charles, Roch-Philippe
    Iezza, Gioia
    Amendola, Elena
    Dankort, David
    McMahon, Martin
    [J]. CANCER RESEARCH, 2011, 71 (11) : 3863 - 3871
  • [7] Increasing Incidence of Differentiated Thyroid Cancer in the United States, 1988-2005
    Chen, Amy Y.
    Jemal, Ahmedin
    Ward, Elizabeth M.
    [J]. CANCER, 2009, 115 (16) : 3801 - 3807
  • [8] Chu J., 2014, BIOINFORMATICS
  • [9] Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
    Ciampi, R
    Knauf, JA
    Kerler, R
    Gandhi, M
    Zhu, ZW
    Nikiforova, MN
    Rabes, HM
    Fagin, JA
    Nikiforov, YE
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (01) : 94 - 101
  • [10] Mutual exclusivity analysis identifies oncogenic network modules
    Ciriello, Giovanni
    Cerami, Ethan
    Sander, Chris
    Schultz, Nikolaus
    [J]. GENOME RESEARCH, 2012, 22 (02) : 398 - 406